Navigation Links
Purdue researcher invents molecule that stops SARS

WEST LAFAYETTE, Ind. - A Purdue University researcher has created a compound that prevents replication of the virus that causes SARS and could lead to a treatment for the disease.

"The outbreak of SARS in 2003 led to hundreds of deaths and thousands of illnesses, and there is currently no treatment," said Arun Ghosh, the Purdue professor that led the molecular design team. "Although it is not currently a threat, there is the concern that SARS could return or be used as a biological weapon. It is important to develop a treatment as a safeguard."

According to the Centers for Disease Control and Prevention, the virus can be transmitted through coughing or sneezing, and the infection can quickly spread from person to person. SARS, or Severe Acute Respiratory Syndrome, spread through two dozen countries over a period of a few months before it was contained. A total of 8,098 people worldwide became ill and 774 died.

In addition to its ability to block the SARS virus, the molecular compound that inhibits the virus provides new insights into a group of proteins found in a range of diseases including childhood croup, herpes and cancer, Ghosh said.

"The molecular inhibitor we developed is very potent against the SARS virus by binding to and blocking the use of a specific protein, called papain-like protease, or PLpro, involved in viral replication and evasion of the immune system," said Ghosh who has a joint appointment in chemistry and medicinal chemistry and molecular pharmacology. "This is the first design and discovery of an inhibitor for this class of proteins. We are hopeful that this will open the door to new treatments for other diseases as well."

Ghosh's group teamed with a research group led by Andrew Mesecar at the University of Illinois at Chicago. The National Institutes of Health infectious disease biodefense program selected the team and funded the research that has been published in the online version of the journal Proceedings of the National Academy of Sciences.

Mesecar's team screened more than 50,000 chemical compounds for the necessary properties to both block the virus and have the potential to become viable drug treatments.

"Only two of the compounds we tested were identified as having the properties researchers believed could become drugs," said Mesecar, a professor of medicinal chemistry and pharmacognosy. "Using those two compounds, Arun Ghosh and his team increased the potency by almost two orders of magnitude."

Ghosh, who invented the HIV drug darunavir that entered the market in 2007, specializes in improving the treatment properties of molecular inhibitors through structure-based design.

"The design of this inhibitor was a challenge because we did not know the structure of the compound, which shows us how an inhibitor works and what parts need to be amplified or changed," Ghosh said.

Kiira Ratia, a graduate student at the University of Illinois, provided a breakthrough when she captured the X-ray structure of the inhibitor molecule bound to the protein. The structure confirmed that the inhibitor would be a good candidate for drug development because it showed that the inhibitor did not bond too strongly to the protein, Ghosh said.

"This was the first time the structure was revealed and we could see that the inhibitor filled the active site of the protein without using strong covalent bonds," he said. "This is very important for development of a therapeutic treatment because it means there is less of a chance for adverse side effects or toxicity, and the treatment can be easily reversed."

Often a protein involved in the disease process also plays a role in regular human biological processes. A safe and effective treatment needs to block enough of the protein to cripple the disease while not completely eliminating the protein from a person's system. It also must work through interactions that are easily reversed by ending treatment, he said.

The inhibitor has only been tested in the laboratory. It must be developed into a drug treatment and evaluated by the U.S. Food and Drug Administration before it could be used by patients, Ghosh said.

In addition to Ghosh and Mesecar, co-authors of the paper detailing this work include, Ratia, Scott Pegan, Wentao Fu, Michael E. Johnson, Melissa Coughlin and Bellur S. Prabhakar from the University of Illinois; Jun Takayama from Purdue University; and Katrina Sleeman and Srendranath Baliji from Loyola University Chicago Stritch School of Medicine.

The team is evaluating the potential to design similar inhibitors for cancer and continues to work with the SARS inhibitor to create even more effective compounds.


Contact: Elizabeth K. Gardner
Purdue University

Related biology technology :

1. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
2. Purdue leads center to simulate behavior of micro-electromechanical systems
3. Purdue creating wireless sensors to monitor bearings in jet engines
4. Duke researchers coax bright white light from unexpected source
5. Pitt researchers create nontoxic clean-up method for potentially toxic nano materials
6. USC researchers print dense lattice of transparent nanotube transistors on flexible base
7. New Online Video Features Brazilian Researcher Elbio Rech
8. J. Craig Venter Institute Researchers Publish Significant Advance in Genome Assembly Technology
9. Virginia Tech researchers discover how mosquitoes avoid succumbing to viruses they transmit
10. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
11. Self-powered devices possible, says Texas A&M researcher
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):